In Comparison of Standard Treatment and Sustained Inflations for Extremely Preterm Infants, Standard Treatment Prevails
PHILADELPHIA, March 26, 2019 /PRNewswire/ -- Preterm infants must establish regular breathing patterns at delivery. For extremely preterm infants requiring resuscitation at birth, a ventilation strategy involving two sustained inflations, compared with standard intermittent positive pressure ventilation, did not reduce the risk of bronchopulmonary dysplasia (BPD) or death at 36 weeks postmenstrual age.
Researchers compared the two methods in a large, multicenter trial led by Children's Hospital of Philadelphia. The findings were published in the March 26, 2019 edition of the Journal of the American Medical Association.
Studies comparing the two methods have been limited thus far. Pooled data from smaller randomized trials were conflicting: one showed that sustained inflations reduced the need for mechanical ventilation. However, another found no benefit in mortality. In infants younger than 30 weeks gestational age, sustained inflations are commonly used in delivery rooms in Europe, but not in the United States.
"Preterm infants with weak respiratory muscles and liquid-filled lungs struggle to aerate their lungs, leaving them at risk of complications, including Bronchopulmonary Dysplasia (BPD), which is associated with a lot of long-term problems," said Haresh Kirpalani, MD, MSc, neonatologist at Children's Hospital of Philadelphia and the study's lead author. "We hypothesized that establishing adequate lung volume quickly in these infants could reduce the risk of BPD. This was possible using sustained inflations at delivery, as these appeared beneficial in animal models, and in smaller prior human studies. However, in our larger randomized trial, in the smallest and most vulnerable preterm infants, this proved not to be the case."
The randomized trial was conducted from August 2014 to September 2017, in 18 neonatal intensive care units in nine countries. Preterm infants from 23 to 26 weeks gestational age requiring resuscitation with inadequate respiratory effort or bradycardia were enrolled. The primary outcome was the rate of BPD or death at 36 weeks postmenstrual age. There were 27 prespecified secondary efficacy outcomes and seven safety outcomes, including death at less than 48 hours.
Among 460 infants randomized (mean gestational age, 25.30 weeks; 50.2 percent female), 426 infants (92.6 percent) completed the trial. In the sustained inflation group, 137 infants (63.7 percent) died or survived with BPD as compared to 125 infants (59.2 percent) in the standard resuscitation group. Death at less than 48 hours of age occurred in 16 infants (7.4 percent) in the sustained inflation group compared with 3 infants (1.4 percent) in the standard resuscitation group. Of 27 secondary efficacy outcomes assessed by 36 weeks' postmenstrual age, 26 showed no significant difference between groups.
"Because we had been worried about complications, the external data safety monitoring board was looking for early adverse events. Unfortunately, this promising therapy seemed to have higher mortality, especially in the smallest, most vulnerable infants," added Kirpalani. "Additional research is needed to address how best to treat these infants at delivery, to reduce their risk of extreme side effects of a very early birth."
Haresh Kirpalani, BM, MSc, et al. for the SAIL Site Investigators. Effect of Sustained Inflations vs Intermittent Positive Pressure Ventilation on Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants: The SAIL Randomized Clinical Trial. JAMA. 2019;321(12):1165-1175. doi:10.1001/jama.2019.1660
About Children's Hospital of Philadelphia: Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals, and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 564-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu
Contact: Joey McCool Ryan
(267) 426-6070
[email protected]
SOURCE Children's Hospital of Philadelphia
Share this article